The “stacked” pipeline of biotech specialty crops and regulatory/market barriers to coexistence
MetadataShow full item record
Redick, Thomas P
Biotech specialty crops face a number of potential barriers. Regulatory uncertainty over new plant-breeding methods and costly overseas approvals could complicate plans for commercialization. Stacking a generic crop aids innovators in the marketplace, but generic crops may need the regulatory data held by patent holders to achieve regulatory approval. Sustainability standards may arbitrarily deny use of biotechnology. Any innovator heading into this sector will need to be aware of all the potential threats awaiting these exciting opportunities in genetic engineering of biotech crops.
Agricultural biotechnology; specialty crops; transgenic papaya; stakeholders; genetic engineering; GE; GMO; regulation; food safety; USDA; novel traits; premarket approval; intellectual property; patents; human health impacts; synthetic genomics
Except where otherwise noted, this item's license is described as CC BY-NC-ND